Press Release

April 29, 2021
1 min read

Alcon to acquire US commercialization rights to Simbrinza


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Alcon has signed an agreement to receive U.S. commercialization rights to Simbrinza from Novartis, according to a press release.

Simbrinza (brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension) is indicated to reduce IOP in patients with primary open-angle glaucoma or ocular hypertension.

Alcon will pay $355 million to Novartis upon closing the agreement.
Source: Adobe Stock

“As the global leader in eye care, the addition of a proven fixed-combination glaucoma therapy is a natural adjacency to our existing portfolio,” Sergio Duplan, president, North America at Alcon, said in the release.

Upon closing, expected in the second quarter of 2021, Alcon will pay $355 million to Novartis. Novartis will continue to sell Simbrinza through a transition period and transfer net profits to Alcon. After the transition, Alcon will manufacture and commercialize Simbrinza for the U.S. market, and Novartis will have the rights to the drop outside of the United States.